Introducing a proline in the α1 M2-M3 linker relieves a molecular brake on channel activation in α1β2γ2 GABAA receptors Authors: Netrang G. Desai, Pranavi Garlapati, Cecilia M. Borghese, Marcel P. Goldschen-Ohm, Uwe Rudolph, Uwe Rudolph, Uwe Rudolph, Uwe Rudolph Published: 2026 ABSTRACT GABAA receptors (GABAARs) are pentameric ligand-gated ion channels (pLGICs) essential for inhibitory synaptic transmission throughout the central nervous system. Despite progress in understanding their three-dimensional structure, the molecular basis for how neurotransmitter binding is transduced to ion channel gating remains poorly understood. Furthermore, relatively little is known about the contributions of distinct subunits to this coupling within typical heteromeric receptors. A highly conserved proline (site 1) in the M2-M3 linker of pLGIC subunits is involved in channel gating – e.g., P273 in the GABAAR β2 subunit. In GABAARs, only the β subunits have an additional proline in the M2-M3 linker (site 2) – e.g., β2(P276) – whereas all other subunits have a non-proline at the homologous site 2 position. Here, we investigate the functional contribution of proline at site 2 in distinct subunits of α1β2γ2 GABAARs. We expressed wild type or mutant α1β2γ2 GABAARs in Xenopus laevis oocytes and used two-electrode voltage clamp electrophysiology to record channel currents in response to GABA and/or other ligands. First, we introduced a proline at site 2 in α1 or γ2 subunits: α1(A280P) and γ2(S291P). Second, we replaced the site 2 proline in the β2 subunit with its homologous non-proline residue from α1 or γ2 subunits: β2(P276A) or β2(P276S). We show that α1(A280P) confers enhanced GABA-sensitivity and spontaneous unliganded channel activity, whereas γ2(S291P) has minor effects on channel activation. In contrast, β2(P276A) or β2(P276S) either had no effect or enhanced GABA-activation, respectively, indicating complex functional dependence on the side chain at site 2 in the β2 subunit. When in combination with other substitutions, the presence or absence of α1(A280P) was consistently correlated with enhanced GABA-sensitivity and spontaneous unliganded opening. Thus, introduction of a proline at site 2 in the α1 M2-M3 linker biases the channel towards an activated state and prevents it from remaining closed at rest. Introduction For GABAA receptors (GABAARs) and related pentameric ligand-gated ion channels (pLGICs), coupling of neurotransmitter binding in the extracellular domain (ECD) to gating of the ion channel pore in the transmembrane domain (TMD) involves several loops located at the ECD-TMD interface (Fig 1A) [1–5]. One of these loops, the M2-M3 linker, connects the second and third transmembrane domains, and interacts with ECD loops (Fig 1B) [1, 2, 6–13]. Studies have uncovered asymmetric functional effects of M2-M3 linker perturbations in distinct subunits within typical heteromeric synaptic α1β2γ2 GABAARs [6, 7, 10, 13]. However, the physical basis underlying this asymmetry remains to be fully understood. M2-M3 linker prolines in a synaptic α1β2γ2 GABAAR. (A) Cryo-EM map (PDB: 6X3X) of a human synaptic α1β2γ2 GABAAR in complex with GABA (red) viewed from the top (left) and side (right). (B) Same view as in panel A for the transmembrane domain only. The M2-M3 linkers are colored black. (C) Zoom in of boxed regions in panel B. A highly conserved proline at site 1 in α1, β2, and γ2 subunits is highlighted in grey. A proline at site 2 found in β subunits only and the homologous non-proline residues in α1 and γ2 subunits are highlighted in magenta. The mature protein numeration for β2 and γ2 subunits is the same for rat and human, but the numeration for the rat α1 subunit is (human numeration −1) for most of the subunit. (D) Sequence alignment of the M2-M3 linker regions (black line) for rat α1, β2, and γ2 subunits. Transmembrane helices M2 and M3 are indicated with cylinders above the alignment. Structures visualized using ChimeraX [14]. All pLGICs have a highly conserved proline in the M2-M3 linker at site 1 which is involved in channel gating (Figs 1C,D and 2). Early studies of nicotinic acetylcholine receptors (nAChRs) suggested that a “pin-in-socket” mechanism involving this conserved proline contributes to coupling agonist binding to pore opening [15–22]. Consistent with this idea, substitutions of this proline in homomeric α7 nAChR result in non-functional channels [23]. However, substitutions in other pLGICs such as GABAARs and 5-HT3A receptors do not abolish channel function, indicating that such a mechanism is not requisite in these channels [23–25]. Nonetheless, substitutions of this conserved proline in either α1 or β2 subunits of GABAARs do alter channel gating properties [24, 25], indicating that this proline at least contributes to channel activity. Sequence alignment of M2-M3 transmembrane region for pLGICs. Transmembrane helices M2 and M3 are indicated with cylinders above the alignment. A conserved proline at site 1 across the subunits of pLGIC receptors is highlighted in grey. A proline at site 2 conserved only in β subunits of GABAARs is highlighted in magenta. A proline found at site 3 in nAChR and 5-HT3A subunits is highlighted in salmon. All sequences are from rat, which are very similar to those from humans. Importantly, the overall site 1-3 proline pattern is the same in human subunits. In addition to the highly conserved site 1 proline, cationic nAChRs and 5-HT3A receptors have another proline located at the top of the M3 transmembrane helix (site 3) (Fig 2). One of the proposed mechanisms for gating is the cis-trans isomerization of this site 3 proline which strongly correlates with the channel activation of 5-HT3A receptors [26]. Although GABAARs lack a homologous proline at site 3, they do have an additional proline in the M2-M3 linker which is specific to β subunits only (site 2) (Figs 1C,D and 2). Here, we investigate the functional contribution of proline at site 2 in each distinct subunit within typical synaptic α1β2γ2 GABAARs. We show that introduction of a proline at site 2 in the α1 subunit enhances GABA-sensitivity and prevents the channel from remaining closed at rest. The role of proline at site 2 in the β2 subunit is more ambiguous, with differential effects for alanine or serine substitutions. Nonetheless, across tested combinations of substitutions in multiple subunits, enhanced GABA-sensitivity and spontaneous activity consistently correlated with the presence of a proline at site 2 in the α1 subunit. This suggests that the presence or absence of a proline-induced kink in the α1 M2-M3 linker at site 2 is an important determinant of channel activation. Our observations provide new insight into the subunit-specific effects of M2-M3 linker perturbations on the channel gating of α1β2γ2 GABAARs. Results Introducing a proline at site 2 in the α1 M2-M3 linker enhances channel activation Xenopus laevis oocytes were co-injected with cRNA for α1, β2, and γ2 GABAAR subunits (either wild type or mutants) in a 1:1:10 ratio [27], and current responses to application of ligands was recorded using two-electrode voltage clamp (see representative current tracings in Fig 3). For each oocyte, we measured current responses to 20–40 s pulses of a series of concentrations of GABA to assess activation sensitivity, and finally the response to the co-application of saturating GABA and propofol to estimate maximal channel activation (Fig 4A). Co-application of saturating GABA and another activator, like propofol, is a typical approach for estimating GABA-evoked maximal open probability [28]. Although this estimation of maximal activation may not reflect conditions where all channels are open with exactly 100% probability, it should be reasonably close. Our logic is that wild-type channels exhibit a maximal open probability of ~0.7–0.8 (70–80%) in saturating GABA [29], which will be increased by addition of propofol. Furthermore, gain-of-function mutations as investigated here will further increase opening. For simplicity, we estimate open probability by assuming it reaches 100% during co-application of saturating GABA and propofol. Importantly, although this approach may slightly overestimate true open probabilities, it will not change our main conclusions regarding enhanced open probability conferred by mutations. Furthermore, using this approach we estimate a peak open probability of 0.74 for wild-type receptors, similar to previous reports [30, 31]. GABA concentration-response curves (CRCs) were normalized to the peak current response elicited by co-application of saturating GABA and propofol and fit with the Hill equation (Eq 1; Fig 4B,C; Table 1). 10.1371/journal.pone.0357367.t001Table 1Parameters for Hill equation fits to normalized GABA CRCs from Fig 4.ReceptorEC50 (µM) H IGABA/Imax n α1β2γ2 86 [75 to 98]1.08 ± 0.050.74 ± 0.0118 α1(A280P) β2 γ2 1.3 [1.3 to 1.4]**1.26 ± 0.021.00 ± 0.01**4 α1 β2(P276A) γ2 62 [40 to 101]1.00 ± 0.150.73 ± 0.034 α1 β2(P276S) γ2 8.7 [5.4 to 15]**1.10 ± 0.200.95 ± 0.04*7 α1 β2 γ2(S291P) 56 [40 to 81]0.94 ± 0.110.85 ± 0.035 α1(A280P) β2(P276A) γ2 4.0 [2.4 to 7.6]*0.86 ± 0.120.86 ± 0.044 α1(A280P) β2(P276S) γ2 9.2 [8.2 to 11]**0.66 ± 0.020.83 ± 0.01**##7 α1(A280P) β2 γ2(S291P) 3.2 [2.1 to 5.3]**0.88 ± 0.110.83 ± 0.03#6 α1 β2(P276A) γ2(S291P) 95 [68 to 141]0.91 ± 0.090.68 ± 0.024Hill equation is defined in Eq 1. EC50 (effective concentration 50) is expressed as mean [95% confidence interval], h (Hill coefficient) and IGABA/Imax (ratio of saturating GABA-induced current to saturating GABA and propofol current) as mean ± SEM, and n is the number of oocytes. log EC50 and IGABA/Imax were analyzed using One-way Brown-Forsythe ANOVA followed by Dunnett's T3 multiple comparisons test.* p < 0.05, ** p < 0.0001 versus α1β2γ2; # p < 0.05, ## p < 0.0001 versus α1(A280P)β2γ2. Parameters for Hill equation fits to normalized GABA CRCs from Fig 4. Hill equation is defined in Eq 1. EC50 (effective concentration 50) is expressed as mean [95% confidence interval], h (Hill coefficient) and IGABA/Imax (ratio of saturating GABA-induced current to saturating GABA and propofol current) as mean ± SEM, and n is the number of oocytes. log EC50 and IGABA/Imax were analyzed using One-way Brown-Forsythe ANOVA followed by Dunnett's T3 multiple comparisons test. * p < 0.05, ** p < 0.0001 versus α1β2γ2; # p < 0.05, ## p < 0.0001 versus α1(A280P)β2γ2. Representative current tracings of wild-type and mutant α1β2γ2 GABAARs. Example two-electrode voltage clamp recordings of wild-type and mutant α1β2γ2 GABAARs. A 10 s pulse of 1 mM picrotoxin (PTX; to assess for unliganded opening) was followed by a series of 20-40 s pulses (sufficient to resolve peak) of increasing concentrations of GABA (µM), a 20 s pulse of saturating GABA in combination with 30 µM propofol (PPF) to estimate the maximal possible current, and a final 10 s pulse of 1 mM PTX. Labeled numeric values for pulses indicate GABA concentration (µM). The substitution α1(A280P) promotes channel activation. (A) Representative current tracing of the mutant α1(A280P) β2(P276S) γ2 GABAAR construct. Peak current responses to increasing concentrations of GABA (µM) followed by a pulse of saturating GABA in combination with 30 µM propofol (PPF). (B, C) Normalized concentration-response curves for GABA-elicited currents. Curves are the Hill equation fit to the means (see Eq 1). Datapoints are plotted as mean ± SEM. See Table 1 for summary statistics of fit parameters and number of oocytes. First, we investigated the effects of introducing a proline at site 2 in the α1 and/or γ2 subunit M2-M3 linker analogous to the naturally occurring proline at the homologous position in the β2 subunit. The substitution α1(A280P) increases GABA sensitivity (i.e., left-shifts the GABA CRC) by ~70-fold (Fig 4B). Furthermore, whereas GABA opens wild type channels with a peak open probability ~0.74, α1(A280P) enhances the efficiency of GABA-activation such that current responses reach a peak open probability of ~1.0 (Fig 4B). In contrast, γ2(S291P) has little effect on channel activation, although there was a small trend towards enhanced activation. The double substitution α1(A280P)β2γ2(S291P) increases GABA sensitivity by ~30-fold, with a similarly modest increase to maximal opening as for γ2(S291P) alone (Fig 4B). Thus, there is some non-additivity in the effects of the double mutant, although α1(A280P) is the more dominant substitution overall. In summary, introduction of a proline at site 2 in the α1 subunit sensitizes the channel for activation by GABA. Substituting the site 2 proline in the β2 M2-M3 linker has sidechain-dependent effects on channel activation We investigated the effects of replacing the site 2 proline in the β2 subunit with the homologous alanine or serine in α1 or γ2 subunits, respectively. The substitution β2(P276S) enhances GABA-sensitivity (i.e., left-shifts the CRC) by ~10-fold and confers an enhanced maximal GABA-elicited peak open probability of ~0.9 (Fig 4C). In contrast, β2(P276A) has no effect on channel activation. Thus, there is a more complex dependence of channel activation on the properties of the sidechain at site 2 in β2 subunits than simply whether it is a proline. We further evaluated double substitutions that effectively move the proline from β2 to α1 or γ2 subunits. Both α1(A280P)β2(P276S)γ2 and α1(A280P)β2(P276A)γ2 receptors show increased GABA-sensitivity and enhanced maximal open probability similar to that of receptors containing either α1(A280P) or β2(P276S) mutations (Fig 4C). Although the underlying mechanism for the differential effects of alanine or serine substitution at β2(P276) are unclear, the observation that introduction of a proline at site 2 in the α1 subunit enhances channel activation is also observed in the tested double substitutions. All combinations that contain the α1 mutant have similarly enhanced gating, irrespective of whether or not a mutation is present in the β2 subunit. Introducing a proline at site 2 in the α1 M2-M3 linker prevents channels from remaining closed at rest To assay for any spontaneous unliganded channel opening in the mutants, we applied the pore blocker picrotoxin (PTX) (Fig 5A,B). The unliganded channel open probability (Popen) was estimated as the ratio of PTX-sensitive current to the total current from the baseline in PTX to the peak current elicited by the combination of saturating GABA and propofol (Eq 2), as illustrated in Fig 5A and as discussed above. Wild-type channels are essentially closed at rest with an unliganded Popen ≤ 0.002 or 0.2% [7, 32]. This is likely an overestimation limited by noise in the recordings, whereas estimates from highly expressing oocytes suggest a much lower unliganded Popen of 1 × 10−5 (0.001%) [31], which is more consistent with the activation energy estimated from the temperature-dependence of GABA binding [30]. Here, we assume the wild-type unliganded Popen to be 1 × 10−5. Importantly, our main conclusions do not depend on this approximation and will remain valid even if the unliganded open probability is as high as 0.002. In contrast to wild-type, the substitution α1(A280P) confers obvious PTX-sensitive spontaneous channel activity clearly distinguished from background noise (unliganded Popen = 0.05 or 5%) (Fig 5A-C). The substitution α1(A280P) confers spontaneously open channels. (A) The total current (Itotal) is estimated as the sum of the peak current response to saturating GABA and 30 µM propofol (PPF; Imax) and the current blocked by 1 mM picrotoxin (PTX; IPTX). (B) Representative tracings of wild-type and mutant α1β2γ2 GABAAR constructs showing the peak current response to saturating GABA and 30 µM propofol and PTX-sensitive currents. (C) The unliganded Popen is estimated as the ratio of PTX-sensitive current to the total current (IPTX/Itotal). Box plots indicate median and quartiles. P-values < 0.05 for Brown-Forsythe ANOVA with posthoc Dunnett’s T3 test are shown. (D) Diagram of estimated closed-open free energy differences (ΔG) for wild type and α1(A280P) containing mutant receptors. Arrows contrast energetic effects of mutations with the energy transduced from GABA binding in wild type receptors. Our experiments place an upper limit on the unliganded Popen for wild type receptors of 0.2% (dotted line), but a prior study estimates a much lower unliganded Popen of ~0.001% [31]. The black arrow shows the energy transduced from binding of two GABA molecules to opening of the pore in wild type receptors. The other arrows show the estimated energetic changes to the closed-open equilibrium conferred by the indicated mutations in the absence of GABA. See Table 2 for summary statistics and number of oocytes. To verify that this spontaneous current did not come from a sub-population of either α1(A280P) or β2 homomers [33, 34] that might arise from mutation-induced changes in subunit assembly, we compared oocytes injected with either α1β2γ2, α1(A280P)β2γ2, α1(A280P), or β2 subunits. For each condition, we injected the same amount of RNA per subunit (1 ng each for α and β subunits, 10 ng for γ). For oocytes injected with heteromeric combinations of α1β2γ2 or α1(A280P)β2γ2 subunits we observed robust GABA-evoked responses. In contrast, for oocytes injected with isolated α1(A280P) or β2 subunits, we saw no evidence for any current responses to GABA or propofol, nor any PTX-sensitive spontaneous current (S1 Fig). Thus, we conclude that our observations for site 2 mutants reflect the behavior of heteromeric receptors with α1, β2, and γ2 subunits (or mutants thereof). All tested combinations of substitutions that included a proline at site 2 in the α1 subunit show noticeable unliganded openings with probabilities of a few percent. The double substitution α1(A280P)β2(P276S)γ2 conferred the most spontaneous channel activity (unliganded Popen = 0.06 or 6%) (Fig 5A-C). Although the P-values for comparison of spontaneous activity in wild-type versus α1(A280P)β2γ2 and α1(A280P)β2(P276A)γ2 are at the limit of significance, we observe distinct PTX-sensitive currents for the mutants that clearly differ from the background holding current (Fig 5A-C). In contrast, responses to PTX for wild-type receptors are nearly indiscernible from noise. Thus, the effects of α1(A280P) containing mutants on spontaneous channel activity are clearly evident. Although this unliganded activity of a few percent is rather small in comparison to maximal GABA-evoked opening, it is nonetheless indicative of a relatively sizeable energetic perturbation to the closed-open equilibrium. This is because the energy difference between closed and open states (Eq 3) needs to change appreciably before channel opening can even be reliably detected in two-electrode voltage clamp recordings. For a wild-type channel, we estimate that activation by two GABA molecules results in a change in open probability from 0.001% to 74%, which represents a change in free energy of −7.4 kcal/mol (see Eq 3; Fig 5D; Table 2). This is similar to the −8.9 kcal/mol estimated from the temperature-dependence of GABA binding [30]. Similarly, the energy required to reach an open probability of 5% is −5.0 kcal/mol. Thus, mutants that are spontaneously open with 5% probability in the absence of ligand have shifted the closed-open equilibrium by an amount that is ~ 2/3rd of that induced by GABA binding in wild-type receptors (Fig 5D). Even if we assume that channels start with a higher unliganded Popen of 0.2% (an upper limit that likely overestimates the true basal opening), the same logic still suggests that mutants exhibiting only a few percent unliganded activity have shifted the gating equilibrium by ~1/3rd of that induced by GABA binding in wild-type receptors (Fig 5D). As such, even a small observable increase in spontaneous activity represents a significant energetic destabilization of the closed state. Thus, introduction of a proline at site 2 in the α1 subunit prevents the channel from remaining closed at rest. 10.1371/journal.pone.0357367.t002Table 2Summary of unliganded open probabilities from Fig 5.ReceptorUnliganded Popen (%)n†ΔG (kcal/mol)n α1β2γ2 0.21 ± 0.03183.70 ± 0.0817‡ α1(A280P) β2 γ2 5.0 ± 1.1*61.86 ± 0.186 α1 β2(P276A) γ2 0.20 ± 0.0443.72 ± 0.144 α1 β2(P276S) γ2 0.5 ± 0.173.26 ± 0.167 α1 β2 γ2(S291P) 0.8 ± 0.242.96 ± 0.164 α1(A280P) β2(P276A) γ2 1.0 ± 0.2*42.52 ± 0.094 α1(A280P) β2(P276S) γ2 6.0 ± 0.5*71.64 ± 0.067 α1(A280P) β2 γ2(S291P) 2.0 ± 0.3*62.23 ± 0.096 α1 β2(P276A) γ2(S291P) 0.15 ± 0.0343.89 ± 0.124Unliganded Popen (Eq 2) and ΔG (unliganded closed-open free energy; Eq 3) are expressed as mean ± SEM, and n is the number of oocytes. Unliganded Popen was analyzed using One-way Brown-Forsythe ANOVA followed by Dunnett's T3 multiple comparisons test.* p < 0.05 versus α1β2γ2.†In a few cases, the oocyte count is different from Table 1 because the unliganded Popen could not be estimated due to loss of recording stability during the final application of PTX.‡The oocyte count for ΔG is one less than for Popen as one of the Popen values was zero, thus precluding a free energy calculation. Summary of unliganded open probabilities from Fig 5. Unliganded Popen (Eq 2) and ΔG (unliganded closed-open free energy; Eq 3) are expressed as mean ± SEM, and n is the number of oocytes. Unliganded Popen was analyzed using One-way Brown-Forsythe ANOVA followed by Dunnett's T3 multiple comparisons test. * p < 0.05 versus α1β2γ2. †In a few cases, the oocyte count is different from Table 1 because the unliganded Popen could not be estimated due to loss of recording stability during the final application of PTX. ‡The oocyte count for ΔG is one less than for Popen as one of the Popen values was zero, thus precluding a free energy calculation. Discussion We have previously identified M2-M3 linker substitutions in widely expressed heteromeric α1β2γ2 GABAARs with asymmetric subunit-specific effects. For example, alanine substitution of the central residue in the M2-M3 linker of β2 or α1 subunits either enhances or inhibits channel activation, respectively [6]. Ablation of a main-chain hydrogen bond in the β2 subunit M2-M3 linker also enhances channel activation and prevents the channel from remaining closed at rest, whereas analogous hydrogen bond ablation in the α1 subunit has no effect [7]. Given the location of the β2 subunit M2-M3 linker directly below the GABA binding sites, we hypothesized that M2-M3 linkers at GABA-binding (β2) and non-binding (α1, γ2) interfaces may have distinct functional contributions to channel gating. One difference in the amino acid sequences of M2-M3 linkers is the site 2 position, which is a proline in β subunits and a non-proline residue in all other subunits. Given that prolines in nearby positions within or next to the M2-M3 linker (sites 1 and 3) have been implicated as important determinants of channel gating [24–26], we hypothesized that the naturally occurring proline at site 2 in β subunits may contribute to the distinct functional contribution of the β2 M2-M3 linker in α1β2γ2 receptors. To test this hypothesis, we performed various substitutions which swapped proline and non-proline residues at site 2 in α1, β2, and γ2 subunits. Although our results do not unambiguously define the functional requirements for the site 2 residue in distinct subunits, they do provide new insight into the molecular basis for channel gating in this region. We show that introduction of a proline at site 2 in α1 subunits 1) sensitizes the channel to activation by GABA, 2) maximizes the efficiency of GABA activation, and 3) prevents the channel from remaining closed at rest. Injection of RNA encoding either β2 or α1(A280P) subunits alone did not produce GABAA-mediated currents (S1 Fig), suggesting that the spontaneous activity we observe with site 2 mutants reflects activity of heteromeric mutant receptors and not a sub-population of constitutively active homomeric receptors. Another possibility is that the α1(A280P)-containing receptors are incapable of co-assembling with γ2 subunits, and the resulting ternary receptors are therefore more sensitive to GABA. However, α1(A280P)-containing receptors show increased GABA-evoked maximal open probabilities and spontaneous activity, whereas binary αβ receptors would exhibit reduced maximal open probability (Popen = 0.40–0.49) [35, 36] and no spontaneous activity. Therefore, although we cannot discard the possibility that the mutated α1 subunit is no longer co-assembling with γ2, this alone would not explain our observations. We conjecture that introduction of a proline-induced kink allows the α1 M2-M3 linker to more easily move radially outward from a naturally more rigid conformation closer to the channel’s central pore axis, thus priming the channel for activation. This idea is consistent with structural observations showing smaller relative motions of α1 versus β2 subunit M2-M3 linkers between closed and activated conformations of wild type α1β2γ2 receptors [37, 38]. The facilitated gating induced by the substitution α1(A280P) may be specific to the proline rigid structure, as substituting the alanine with a serine has been shown to confer a small decrease in GABA-sensitivity [39]. There is also a trend towards enhanced activity upon introduction of proline at site 2 in the γ2 subunit, although the effect is much smaller than in α1. The weaker effect in γ2 could potentially reflect the expectation that the most probable receptor stoichiometry contains two α1 subunits and only one γ2 subunit [40–43]. Substitution of the naturally occurring site 2 proline in the β2 subunit with serine also enhanced GABA-activation, but substitutions with alanine had no effect. Thus, specific sidechain interactions at this position in β2 are important, but proline is not a requirement. In summary, we show that absence of a proline at site 2 in the α1 subunit is important for channels to remain closed at rest. Our observations are consistent with the idea that the backbone geometry of the M2-M3 linker at site 2 in the α1 subunit is an important determinant of the channel’s activation energy landscape. Materials and methods Mutagenesis and in vitro transcription DNA for wild-type and mutant GABAAR rat α1, β2, and γ2 subunits was subcloned in the pUNIV vector [44]. The mature protein numeration for β2 and γ2 subunits is the same for rat and human, but the numeration for the rat α1 subunit is (human numeration −1) for most of the subunit. Mutations were introduced using QuikChange II (Qiagen) or by GenScript and confirmed by sequencing of the entire subunit. Complementary RNA (cRNA) for each construct was generated (mMessage mMachine T7, Ambion), quantified (Qubit, ThermoFisher Scientific) and quality assessed (TapeStation, Agilent) prior to injection in Xenopus laevis oocytes. Isolation of Xenopus laevis oocytes and injection of cRNA Defolliculated Xenopus laevis oocytes were obtained from EcoCyte Bioscience or harvested from mature female Xenopus laevis frogs (Nasco), which were housed in the University of Texas at Austin animal facility. Frog care and surgery followed the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines and the University of Texas at Austin Institutional Animal Care and Use Committee (IACUC-)-approved protocol (approval number AUP-2021–00216). Frogs were anesthetized via immersion in a 3-aminobenzoic acid ethyl ester (Tricaine) solution (0.23% in water), buffered to a neutral pH using sodium bicarbonate, for a total time period of 40 minutes. Frogs were euthanized using an overdose via immersion in a Tricaine solution (0.5% in water), buffered to a neutral pH using sodium bicarbonate, for a total time period of 3 hours, and then decapitated. Xenopus laevis oocytes were harvested from frogs under tricaine anesthesia. A piece of ovary was removed from the frog, and placed in isolation media (108 mM NaCl, 2 mM KCl, 1 mM EDTA, 10 mM HEPES, pH = 7.5). Oocytes were manually isolated from the thecal and epithelial layers using forceps and then incubated in a collagenase buffer (0.5 mg/mL collagenase from Clostridium histolytic, 83 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES) to remove the follicular layer. Before injections, the defolliculated oocytes were transferred to a sterile incubation solution (88 mM NaCl, 1mM KCl, 2.4 mM NaHCO3, 19 mM HEPES, 0.82 mM MgSO4, 0.33 mM Ca(NO3)2, 0.91 mM CaCl2, 10,000 units/L penicillin, 50 mg/L gentamicin, 90 mg/L theophylline, and 220 mg/L sodium pyruvate, pH = 7.5). Oocytes were injected with 12 ng of total cRNA for α1, β2, and γ2 subunits (wild-type or mutants) in a 1:1:10 ratio (Nanoject, Drummond Scientific). Oocytes were incubated in the sterile incubation solution at 16 ºC. Two-electrode voltage clamp recordings One to three days post injection, currents from channels expressed in Xenopus laevis oocytes were recorded in two-electrode voltage clamp (Oocyte Clamp OC-725C, Warner Instruments), digitized using a PowerLab 4/30 system (ADInstruments) and recorded using LabChart 8 software (ADInstruments). Data was obtained from at least two different batches of oocytes for each experimental group. Oocytes were held at −70 mV and perfused continuously (2 ml/min) with ND96 buffer (96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.5) or ND96 buffer containing picrotoxin (PTX), GABA, or GABA & propofol. PTX was diluted from a 0.5 M stock solution in DMSO. GABA was diluted from a 1 M stock solution in double distilled water stored at −80 °C. Propofol was diluted from a 30 mM stock solution in DMSO such that the final solution contained ≤0.1% V/V DMSO. The recording protocol was as follows: a 10 s pulse of 1mM PTX was followed by a series of 20–40 s pulses of increasing concentrations of GABA, a 20 s pulse of saturating GABA in combination with 30 µM propofol (PPF), and a final 10 s pulse of 1mM PTX. Every recording was bookended by applications of PTX to correct for any drift and to identify the zero current baseline. Pulses were sufficiently long to resolve the peak response and inter-pulse intervals were 5–15 minutes to allow washout with buffer and currents to return to baseline. Current traces were baselined by subtracting a spline fit to manually selected baseline regions in each trace. Baselined traces were then normalized by subtracting the zero current level in PTX and then dividing by the peak response in GABA and propofol. Baselining and normalization were done with custom scripts in MATLAB 2024b (MathWorks). Normalized GABA concentration-response curves (CRCs) were fit with the Hill equation: where I is the magnitude of the GABA-elicited current, Imax is the magnitude of the maximal current response elicited by the co-application of GABA and 30 µM propofol, [GABA] is the GABA concentration, EC50 is the concentration eliciting a half-maximal response, and h is the Hill slope. The unliganded channel open probability (Popen) was estimated as: where IPTX is the PTX-sensitive current and Itotal is the total current from the baseline in PTX to the peak current elicited by the combination of saturating GABA and propofol The closed-open free energy difference (ΔG) was computed as: where R is the gas constant and T is the temperature Statistical analysis Summary data was analyzed using Prism 10 (GraphPad). Symbols and error bars are mean ± SEM, and box plots show median and interquartile intervals. Where applicable, we applied One-way Brown-Forsythe ANOVA followed by Dunnett's T3 multiple comparisons test. We focus on visually evident effects as opposed to relying solely on P-value. For example, effect sizes that are multiple time larger than the variation, or clear current block by PTX well beyond small artifacts that can arise from exchanging solutions. Supporting information No GABAA-mediated currents after injection of single GABAA receptor subunits. Injection of RNA encoding either β2 or α1(A280P) (1 ng/oocyte) did not elicit spontaneous activity (assessed by application of 1 mM picrotoxin, panel A), nor agonist-evoked currents (maximal GABA concentration, panel B, or maximal GABA concentration + 30 µM propofol, panel C). The maximal GABA concentration was chosen based on the trimeric receptor used for comparison: α1β2γ2 for β2 (3 mM GABA) and α1(A280P)β2γ2 for α1(A280P) (100 µM GABA). In comparison, the trimeric receptors showed robust GABA-evoked currents (panel B) that were enhanced by propofol in the wild-type receptor (panel C). In addition, α1(A280P)β2γ2 receptors exhibited spontaneous activity as assessed by current block with picrotoxin (panel A). All recordings were performed in oocytes from the same batch. Data shown as median ± interquartile range. (PDF) An excel file containing raw data used to build Fig 4B,C and Fig 5C. (XLSX) 27 Mar 2026 Dear Dr. Goldschen-Ohm, plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Uwe Rudolph Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript. 3. We note that your Data Availability Statement is currently as follows: All relevant data are within the manuscript and in Supporting Information files. Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition). For example, authors should submit the following data: - The values behind the means, standard deviations and other measures reported; - The values used to build graphs; - The points extracted from images for analysis. Authors do not need to submit their entire data set if only a portion of the data was used in the reported study. If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access. 4. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 5. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: The M23 linker of the LGICs has garnered much attention over the last 2 decades. The proximity of the domain to both the ligand binding and ion channel of the protein have led many to hypothesize that it is a fundamental component of channel gating. This study adds to this body of knowledge. The manuscript describes well performed assays and is clearly written. It articulates a complex relationship between the M23linker and channel activation. I have a few questions, some of which can be addressed with additional prose, others that might need more experiments. 1. Adding/removing prolines can alter protein folding and receptor assembly. Consequently, functional heteropentamers lacking the gamma subunit or beta homomers may be expressed in different ratios to those normally observed. Could these effects account for the increased picrotoxin effect, or changes in EC50? 2. The authors make a strong argument for the role the M23 linker plays in gating. The change in EC50 and block by picrotoxin support this argument. However, use of a partial agonist or single channel experiments would provide stronger evidence. 3. Proline bestows several unique properties on proteins: constraining protein movement and enabling cis-trans conformations in switches. With so many LGIC structures now available, I was surprised to see that the authors did not attempt to model the new structures the mutant subunits may adopt. Modeling is still an imprecise science but can generate useful hypotheses. Even without the models, I would like the authors to suggest how the mutations alter coupling, structure and function. 4. The authors make the interesting statement "Irrespective of P-value, we focus only on relatively large effects." Please quantify large and why p-value can/should be disregarded. Reviewer #2: In the paper entitled “Introducing a proline in the α1 M2-M3 linker relieves a molecular brake on channel activation in α1β2γ2 GABAA receptors” the authors investigated the impact of mutating the so called proline site 2 in the β2 subunits (at the 276 position) and in analogous positions in the α1 and γ2 subunits. They report that α1(A280P) mutation results in enhanced GABA-sensitivity and spontaneous channel activity, whereas the effect of the γ2(S291P) mutation was minor. The impact of the substitution at the site 2 in the β2 subunit depended on the side chain: β2(P276A) had no effect while β2(P276S) increased GABA-sensitivity with a little increase in spontaneous activity. Overall, the authors conclude that the proline site 2 at the β2 subunits and analogous positions at α1 subunit may lead to a significant increase in GABA-sensitivity of the receptor and increased spontaneous activity. The paper provides new and interesting information related to the role of M2-M3 linker, located at the domain interface of GABAAR, known to play a crucial role in the receptor activation process. There are, however, some points that need to be addressed. Major 1. Although, in general, it is difficult to extract some precise information on the time course of measured currents using 2 electrode VC in oocytes but I am curious if the authors made an attempt to analyze the kinetics of current responses which would indicate some alterations in the receptor gating (saturating [GABA]) or in the agonist binding (low [GABA]). A related technical issue is that the methodology section is lacking description of the perfusion system and its exchange time. The time scale bars in Figs. 3-5 refers to a surprisingly long time: 15 min. Is this a mistake ? In similar experiments in other papers (e.g. [29]) typical scale bars refer to seconds, not minutes. 2. Two clues may argue that considered mutations may affect the receptor gating: a marked increase the spontaneous activity and also increased IGABA/Imax at saturating [GABA] for some mutants (Fig. 4). This issue requires a more extensive discussion. Minor 1. Page 5 line 96 statement that “all channels are open with ~100% probability as described previously [29]”. The assumption that GABAAR reaches open probability of 100 % at saturating [GABA] with propofol should be taken with caution. Bai and Orser (1999) used high resolution recordings and have shown that propofol only slightly (8% but significantly) increased response to saturating [GABA] while the assessments of the maximum open probability in these conditions is in the range 0.5-0.8 (e.g. Jones and Westbrook, 1995; et al., 1999; Perrais and Ropert, 1999; Barberis et al., 2000). These estimations argue against maximum Popen of exactly 1.0. Akk group in paper [29] used oocytes and two electrode VC (as in present paper) which offers limited time resolution for which, before the response reaches the peak, a considerable fraction of receptors desensitize hindering precise estimation of maximum open probability at peak. The methodology of describing dose-responses used by authors is correct and the use of propofol which indeed increases Popen is informative but I would recommend not insisting about maximum Popen of 100 %. 2. In the figure 4 A it should be described for which mutant the traces are presented. Without description, at the first glance, the reader may assume that control recordings (for WT receptors) are shown. Analogous remark for the Fig. 5 A. 3. For the sake of completness the value of IGABA/Imax at saturating [GABA] should be provided as for some mutants (e.g. α1(A280P)) this value is clearly increased compared to WT (clearly seen in Fig. 4). For these values the statistical comparison should be made between considered mutants and WT (similarly as for spontaneous activity, Table 2, Fig. 5). 4. The conclusion presented in the sentence page 8 lines 144-147 that "the observation that introduction of a proline at site 2 in the α1 subunit enhances channel activation is still robustly supported by the tested double substitutions" is not clear. Actually, the impact of the α1 subunit mutation appears not to be influenced by the mutation of the β2 subunit (irrespective of A or S substitution) thus it is not clear what is meant for the "robust support" from double substitutions. 5. Page 8, lines 142 and 143. In the description of receptor types γ2 subunit should be added (it looks like α1β2 receptors were studied). 6. There is a semantic issue in the description of the increased spontaneous activity in some of the considered mutants. For instance, in the section title on page 8, lines 148, 149 the information that introduction of proline "prevents channels from remaining closed at rest" is overstated. Data in Fig. 5 actually show a relatively small induction of the spontaneous activity meaning that a minor destabilization of the shut state took place. Probably the authors meant "preventing the channel from remaining permanently closed at rest" but this would be problematic too as WT channels show some (low) spontaneous activity. This statement about “preventing the closed state” is present over and over throughout the manuscript and I would recommend to use a less controversial description of this finding. 7. Page 10, lines 173. Although the intention is clear, the statement that PTX "elicits" current is awkward and confusing (although unfortunately sometimes it is used). PTX blocks currents and thereby reveals current mediated by spontaneously active receptors. 8. In Fig. 5 two p values are just at the limit of significance (0.047 and 0.0483) that is a little but disturbing considering also relatively low number of trials. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Andrew Jenkins Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 29 Apr 2026 See file `Response to Reviewers.docx`. Submitted filename: Response to Reviewers.docx 10 Jun 2026 Dear Dr. Goldschen-Ohm, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 25 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Uwe Rudolph Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: I Don't Know ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes ********** Reviewer #1: 1. I disagree. Sexton et al describes effect of beta2 expression on spontaneous gating in heteromeric receptors. Sexton cites Eaton who in turn cites Cestari who both describe spontaneous activity with beta2 homomers. (PMID: 25238745, 8724679) 2. The authors have not addressed my concern. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: ANDREW JENKINS ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 6 Aug 2026 See included Response to Reviewers document. Submitted filename: Response_to_Reviewers_auresp_2.docx 17 Aug 2026 Introducing a proline in the α1 M2-M3 linker relieves a molecular brake on channel activation in α1β2γ2 GABAA receptors PONE-D-26-12092R2 Dear Dr. Goldschen-Ohm, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Uwe Rudolph Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes ********** Reviewer #1: I commend the authors for providing the additional data. Comparing maximum activation with GABA compared to THIP / Gaboxadol / 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol or 4-PIOL / 4-piperidinol sulfate / P4S would be a cleaner and more straightforward measure of intrinsic efficacy. Propofol is an excellent choice of course, but at 30uM it has a multitude of actions as a positive modulator and agonist and some of the mutations reported here are quite close to the propofol binding/gating sites. If the authors’ hypotheses are correct, partial agonists like THIP or 4-PIOL would show a bigger reduction in efficacy for gating impaired receptors and improved efficacy in gating enhanced mutants. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No ********** PONE-D-26-12092R2 PLOS One Dear Dr. Goldschen-Ohm, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS One and supporting open access. Kind regards, PLOS One Editorial Office Staff on behalf of Dr. Uwe Rudolph Academic Editor PLOS One